血微RNA被确定为轻微认知障碍和阿尔茨海默氏病发展的潜在生物标志。 Blood microRNAs identified as potential biomarkers for mild cognitive impairment and Alzheimer's progression.

最近的研究表明,血液微小RNAs作为诊断轻微认知缺陷(MCI)和预测其演变为老年痴呆症的生物标志的潜力。 Recent studies highlight the potential of blood microRNAs as biomarkers for diagnosing mild cognitive impairment (MCI) and predicting its progression to Alzheimer's dementia. 由波士顿大学和其他方面的研究人员进行的研究结果表明,这些微型RNA系统可以促进早期、非侵入性和成本效益高的测试。 Conducted by researchers from Boston University and others, the findings suggest that these microRNAs could facilitate early, non-invasive, and cost-effective testing. 这一研究可增进对阿尔茨海默氏病机制的了解,为新的治疗目标和早期干预战略铺平道路。 This research may enhance understanding of Alzheimer's mechanisms, paving the way for new therapeutic targets and early intervention strategies.